SpringWorks Therapeutics SWTX announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending conditional ...

Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 billion. The acquisition – which was confirmed to be in the final stages ...

German chemical and pharma group Merck KGaA has acknowledged that it is in talks to buy US biotech SpringWorks, but cautioned there is no guarantee a deal will be forthcoming. Merck said in a ...

In other recent news, SpringWorks Therapeutics has been in the spotlight with several key developments. The company is set to be acquired by Merck (NSE:PROR) KGaA, a move that TD Cowen analysts ...

In other recent news, SpringWorks Therapeutics has been in the spotlight with several key developments. The company is set to be acquired by Merck (NSE:PROR) KGaA, a move that TD Cowen analysts ...

In a bid to boost its foothold in oncology, Merck KGaA late last month announced a deal to purchase cancer-focused Pfizer spinout SpringWorks Therapeutics for $3.9 billion. The health of Merck ...

The German pharmaceutical company Merck KGaA is negotiating the acquisition of the American manufacturer of drugs for the treatment of cancer and rare diseases SpringWorks Therapeutics Inc. This is ...

Merck has announced the acquisition of SpringWorks, which is expected to close this year, for an enterprise value of EUR 3 billion. While the deal appears expensive at an 18 times price/sales ...

NF1 drug development accelerates with novel treatments aiming to surpass current MEK inhibitors in efficacy, safety, and patient-friendly delivery. The evolving NF1 landscape highlights how innovation ...

SpringWorks is fully aligned with the business ... Thank you, Florian, and thank you everyone for your continued interest in Merck. To summarize, we had a solid start into the year, clearly ...

The bottom line: As we anticipate the announced acquisition of Springworks to close, we updated our model, changing our fair value estimate for narrow-moat Merck KGaA to EUR 142 from EUR 148.